ClinicalTrials.gov
ClinicalTrials.gov Menu

Cognitive Training and Neuroplasticity in Mild Cognitive Impairment (CogTraining)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03205709
Recruitment Status : Recruiting
First Posted : July 2, 2017
Last Update Posted : November 7, 2018
Sponsor:
Collaborators:
Duke University
Queens College, The City University of New York
Information provided by (Responsible Party):
Davangere P. Devanand, New York State Psychiatric Institute

Brief Summary:
The purpose of this study is to evaluate if systematic cognitive training can improve cognitive performance in participants (55 and older) with memory loss. This study will evaluate the effects of Computerized Cognitive Training (CCT) for improvement in everyday cognitive and function status, in addition to long-term changes in brain networks over an 18-month period. Although there is no distribution of medication for this study, participants are required to have an at-home computer.

Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment Memory Disorders Memory Impairment Cognitive Impairment Cognitive Disorder Cognitive Decline Other: Computerized Cognitive Training Other: Crossword Puzzles Not Applicable

Detailed Description:
In this clinical trial, investigators will evaluate if systematic cognitive training can improve cognitive performance in participants with memory loss. This study is for those who have demonstrated difficulty with memory. It will evaluate the effects of Computerized Cognitive Training (CCT) for improvement in everyday cognitive and function status, in addition to long-term changes in brain networks over an 18-month period. In this study, participants will be randomly assigned to Training Group 1 or 2; therefore, one will have a 50% chance of being assigned to CCT, and a 50% chance of being assigned to Crossword Puzzle Training (CPT). During the 18- month period, participants will be asked to come to the Memory Disorders Clinic at the New York State Psychiatric Institute (NYSPI) for a screening evaluation, and if eligible, will return for five follow-up visits at Weeks 12, 32, 52, and 78.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Cognitive Training and Neuroplasticity in Mild Cognitive Impairment
Actual Study Start Date : November 29, 2017
Estimated Primary Completion Date : July 31, 2022
Estimated Study Completion Date : July 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Memory

Arm Intervention/treatment
Active Comparator: Training Group 1
Computerized Cognitive Training
Other: Computerized Cognitive Training
Computerized online cognitive training will be used to target specific cognitive abilities and neural networks to potentially improve cognitive functioning through neuroplasticity.

Placebo Comparator: Training Group 2
Crossword puzzles
Other: Crossword Puzzles
These are intended to mimic crossword puzzles in newspapers.




Primary Outcome Measures :
  1. Change overtime in the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) [ Time Frame: [Time Frame: Baseline, Weeks 12, 52, 78] ]
    The modified ADAS-Cog is a cognitive battery that assesses learning, memory, language production, language comprehension, constructional praxis, ideational praxis, and orientation.

  2. UPSA [ Time Frame: [Time Frame: Baseline, Weeks 32, 78] ]
    It is a performance-based measure of functional abilities that includes measures of simulated real-world activities, for example, planning a trip to the beach, remembering documents to bring to a medical appointment, and dialing a phone number.


Secondary Outcome Measures :
  1. Neuropsychological Testing Composite Score [ Time Frame: [Time Frame: Baseline, Weeks 12, 52, 78] ]
    Neuropsychological Testing Composite Score is a compiled score of all neuropsychological tests administered in the protocol, i.e. Auditory Verbal Learning Test, Block Design, Verbal Fluency, Visual Reproduction, Boston Naming Task, Trails A and B

  2. Change overtime in Pfeffer Functional Activities Questionnaire (FAQ) [ Time Frame: [Time Frame: Screen, Weeks 12, 20, 32 52, 78] ]
    FAQ is a widely used 10-item instrument that takes 3 minutes to administer and focuses on instrumental, social and cognitive functioning.


Other Outcome Measures:
  1. Geriatric Depression Scale [ Time Frame: [Time Frame: Screen, Weeks 12, 32, 52, 78) ]
    Used to assess depression

  2. MMSE (Mini Mental Status Exam) [ Time Frame: [Time Frame: Screen, Weeks 12, 32 52, 78] ]
    A 30-point questionnaire that is widely used in clinical research to measure cognitive impairment.

  3. WMS-III Logical Memory I & II [ Time Frame: [Time Frame: Screen] ]
    Used to measure logical memory function in an individual. Participant is read stories, and asked to remember the story's details at two different time points.

  4. Block Design [ Time Frame: [Time Frame: Baseline, Weeks 12, 52, 78] ]
    Block Design is primarily a measure of visual-spatial and organizational processing abilities, as well as nonverbal problem-solving skills.

  5. Verbal Fluency [ Time Frame: [Time Frame: Baseline, Weeks 12, 52, 78] ]
    Assesses phonemic fluency by requesting the participant to orally produce as many words as possible that begin with certain letters within a 60-second time period.

  6. Boston Naming Task [ Time Frame: [Time Frame: Baseline, Weeks 12, 52, 78] ]
    It is a confrontational word retrieval task for 60-items.

  7. Trails A and B [ Time Frame: [Time Frame: Baseline, Weeks 12, 52, 78] ]
    Parts A and B are composed of 25 circles. Patients are asked to scan the entire page and identify the next number or letter in a sequence.

  8. User engagement scale [ Time Frame: [Time Frame: Week 12, 78] ]
    This measures (version adapted for computer games) multiple aspects of engagement, usability and satisfaction on a 5-point Likert scale and comprises both negative ("I felt annoyed when on this site", "the game was confusing") and positive ("I really had fun", "It was really worthwhile") items.

  9. UPSIT (University of Pennsylvania Smell Identification Test) [ Time Frame: [Time Frame: Baseline, Week 78) ]
    This assesses olfactory identification deficits. Participants will be asked to scratch smells in testing booklets, and choose the selection that best corresponds to the odor that is being emitted.

  10. Cognitive Reserve Index [ Time Frame: [Time Frame: Screen] ]
    A brief questionnaire assessing for cognitive reserve.

  11. Change overtime in the Neurocognitive Performance Test [ Time Frame: [Time Frame: Baseline, Weeks 12, 78] ]
    NCPT is a set of assessments that test your skills using tasks independent of the Lumosity games. This test is completed online using your Lumosity login.

  12. Visual Reproduction Test [ Time Frame: [Time Frame: Baseline, Weeks 12, 52, 78] ]
    A test used to assess visual memory.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females 55 to 95 years of age (inclusive) at the time of informed consent.
  2. Subjective cognitive complaints, i.e., memory or other cognitive complaints, e.g., naming/language.
  3. Meets criteria for cognitive impairment (CI) defined as scores > 1 below standardized norms on memory function as identified by the Wechsler Memory Scale (WMS) III Logical Memory immediate or delayed recall score.
  4. Folstein Mini Mental State (MMSE) score ≥ 23 out of 30.
  5. A family member or other individual who is in contact with the patient and consents to serve as informant during the study; this can be a telephone informant in the case of patients who do not have a live-in informant or close significant other.
  6. Access to a home desktop or laptop computer at acceptable internet speed for the study duration.

Exclusion Criteria:

  1. Diagnosis of dementia of any type.
  2. Current clinical evidence of schizophrenia, schizoaffective disorder, major depression, psychosis, or bipolar I disorder (DSM-IV criteria).
  3. Active suicidal ideation or plan.
  4. Current or recent (past 6 months) alcohol or substance use disorder (DSM-5 criteria).
  5. Clinical stroke with residual neurological deficits. While we will not exclude patients with cerebrovascular disease, we will not include patients who have had a stroke with residual clinical deficits because it is not clear that this type of patient is similar to the MCI (Mild Cognitive Impairment) patient generally, and clear-cut neurological impairment, e.g., hemiplegia/hemiparesis or speech impairment, may compromise the patient's ability to do the CCT or active control procedures and to complete the neuropsychological test battery.
  6. Use of medications known to have a negative impact on cognition: benzodiazepines in lorazepam equivalents greater than or equal to 1 mg daily, narcotics, anticholinergics. Other patients receive medications that may be associated with cognitive impairment but are rarely considered the likely etiology, e.g., theophylline, nifedipine, beta blockers; they will not be excluded. Patients receiving other psychotropic medications not expected to have a material impact on cognition, e.g., SSRIs (Selective Serotonin Reuptake Inhibitors) and SNRIs (Serotonin-norepinephrine reuptake inhibitors) will be eligible.
  7. Presence of any of the following disorders: a) Central Nervous System infection, with cerebrospinal fluid evidence of meningitis, encephalitis, or other infectious process; b) dementia of any type; c) Huntington's disease; d) Multiple sclerosis; e) Parkinson's disease; f) Other neurologic disorders with focal signs, e.g., amyotrophic lateral sclerosis; g) Mental retardation.
  8. Acute, severe unstable medical illness. For cancer, acutely ill patients (including those with metastases) will be excluded, but past history of successfully treated cancer will not result in exclusion.
  9. Contraindication to MRI scan: pacemaker, metal implants following surgery, any other contraindication to MRI. Eligibility for the MRI scan is a requirement for the study.
  10. UPSIT (University of Pennsylvania Smell Identification Test) exclusions: current smoker > 1 pack daily, current upper respiratory infection (retested as soon as the infection clears). UPSIT scores are reduced in schizophrenia, Parkinson's disease and Parkinson's related conditions; these disorders are exclusion criteria for this study. Patients with UPSIT exclusions, e.g., current heavy smoker (less than 3% of older adults in our experience), will not receive the UPSIT but will continue to participate in all other aspects of the study.
  11. Patients lacking English-speaking ability as determined by self-report and clinical evaluation.
  12. Regular online brain training or regular crossword puzzle user, defined as doing these procedures at a frequency of twice weekly or greater during the year prior to screening. Eligible participants who join the trial are instructed not to do these procedures on their own during the trial, i.e., independent of the study.
  13. Participation in another intervention trial for cognitive impairment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03205709


Contacts
Contact: Jessica L D'Antonio, BA 646-774-8674 jessica.dantonio@nyspi.columbia.edu
Contact: Laura Simon-Pearson, BA 646-774-8671 laura.simonpearson@nyspi.columbia.edu

Locations
United States, New York
New York State Psychiatric Institute Recruiting
New York, New York, United States, 10032
Contact: Jessica L D'Antonio, B.A    646-774-8674    jessica.dantonio@nyspi.columbia.edu   
Contact: Laura Simon-Pearson, B.A    646-774-8671    laura.simonpearson@nyspi.columbia.edu   
Principal Investigator: Davangere Devanand, M.D.         
Sub-Investigator: Terry Goldberg, PhD         
Sub-Investigator: Nancy Kerner, M.D.         
United States, North Carolina
Duke University Recruiting
Durham, North Carolina, United States, 27710
Contact: Caroline Hellegers, MA    919-681-3986    caroline.hellegers@duke.edu   
Principal Investigator: Murali Doraiswamy, MD         
Sponsors and Collaborators
New York State Psychiatric Institute
Duke University
Queens College, The City University of New York
Investigators
Principal Investigator: Davangere P Devanand, MD Columbia University
Principal Investigator: Murali Doraiswamy, MD Duke University
Principal Investigator: Joel Sneed, PhD Queens College

Responsible Party: Davangere P. Devanand, Professor of Clinical Psychiatry and Neurology, New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT03205709     History of Changes
Other Study ID Numbers: 7395
First Posted: July 2, 2017    Key Record Dates
Last Update Posted: November 7, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Davangere P. Devanand, New York State Psychiatric Institute:
memory
computerized training
cognition
MRI
mci
memory problems
memory complaints

Additional relevant MeSH terms:
Disease
Cognitive Dysfunction
Cognition Disorders
Memory Disorders
Pathologic Processes
Neurocognitive Disorders
Mental Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms